Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-02-01
2008-11-25
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S375000, C435S376000, C435S006120, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07456154
ABSTRACT:
The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
REFERENCES:
patent: 5455044 (1995-10-01), Kim et al.
patent: 5558852 (1996-09-01), Bigner et al.
patent: 5891725 (1999-04-01), Soreq et al.
patent: 6110742 (2000-08-01), Soreq et al.
patent: 7074915 (2006-07-01), Soreq et al.
patent: WO 9822132 (1998-05-01), None
patent: WO 9826062 (1998-06-01), None
patent: WO 0136627 (2001-05-01), None
Abe et al. (1998) Antivir. Chem. Chemother. 9, 253-62.
Agrawal S. and Kandimalla E.R. (2000) Mol. Med. Today, 6, 72-81.
Andres et al., Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin Iβ gene expression followed by late-onset neuromotor deterioration.Proc. Natl. Acad. Sci. USA. 94:8173-8178 (1997).
Bai et al. (1998) Ann Thorac. Surg. 66, 814-9.
Ben Nathan D. et al. (1991) Life .Sci. 48, 1493-1500.
Ben Aziz-Aloya et al., Expression of human acetylcholinesterase promoter-reporter construct in developing neuromuscular junctions ofXenopusembryos.Proc. Natl. Acad. Sci. USA. 90:2471-2475 (1993).
Berrouschot et al. (1997) Crit. Care Med. 25, 1228-35.
Bochot et al. (1998) Pharm. Res. 15, 1364-9.
Boneva, N. et al. (2000) Muscle & Nerve 23, 1204-8.
Capaccioli et al.(1993) Biochem. Biophys. Res. Comm. 197, 818.
Cohen, O. et al. (2002) Mol. Psychiatry 7, 874-885 Conaty et al. (1999) Nucleic Acids Res. 27, 2400-2407.
Cohen, O. et al. (2002) Mol. Psychiatry 7, 874-885 Conaty et al. (1999) Nucleic Acids Res. 27, 2400-2407.
Conaty et al. (1999) Nucleic Acids Res. 27, 2400-2407.
Crooke S.T. (2000) Methods Enzymol. 313, 3-45.
de Angelis, L.M. (2001) JV. Engl. JMed. 344(2), 114-123.
Drachman, D.B. (1994) N Engl J Med 330, 1797-810.
Ellman et al., A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity.Biochemical Pharmacology. 7:88-95 (1961).
Ellman et al., A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity.Biochemical Pharmacology. 7:88-95 (1961).
Friedman et al., Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response.Nature Medicine. 2:1382-1385 (1996).
Galyam, N. et al. (2001) Antisense Nucl Acid Drug Dev 11, 51-57.
Gerster et al. (1998) Anal. Biochem. 262, 177-84.
Goldstein and Betz (1986) Scientific American, September, pp. 70-79.
Grifman M., and Soreq, H. (1997) Antisense Nucleic Acid Drug Dev 7, 351-9.
Grisaru D. et al. (2001) Mol. Med. 7, 93-105.
Hall and Sanes (1993) Cell 72 /Neuron vol. 10 (Suppl.), 99-121.
Haseloff and Gerlach (1988) Nature 334, p. 585-591.
Imperato A. et al. (1991) Brain Res. 538, 111-117.
Kanamaru et al. (1998) J. Drug Target. 5, 235-46.
Kaufer et al., Acute stress facilitates long-lasting changes in cholinergic gene expression.Nature. 393:373-377 (1998).
Kita and Saito (1999) Int. J. Cancer 80, 553-8.
Koenigsberger C. et al. (1997) J. Neurochem. 69, 1389-1397.
Koenisberger et al., Neurite Differentiation Is Modulated in Neuroblastoma Cells Engineered for Altered Acetylcholinesterase Expression.J. Neurochem. 69:1389-1397 (1997).
Legay et al. (1993) J. Neurochem. 60(1), 337-346.
Lesnik, E.A. & Freier, S.M. (1998) Biochemistry 37, 6991-7.
Lev-Lehman et al., Synaptogenesis and Myopathy Under Acetylcholinesterase Overexpression.J. Mol. Neurosci. 14:93-105 (2000).
Meshorer et al., Alternative Splicing and Neuritic mRNA Translocation Under Long-Term Neuronal Hypersensitivity.Science. 295:508-512 (2002).
Meyer et al., Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides.J. Biol. Chem. 273(25):15621-15627 (1998).
Monia, B. P. (1997) Ciba Found. Symp. 209, 107-119.
Nakamura et al. (1998) Gene Ther. 5, 1455-61.
Noguchi et al. (1998) FEBS Lett. 433, 169-73.
Perez Ruiz (1999) Antisense Nucleic Acid Drug Dev., 9-33.
Quattron et al.(1995) Biochemica 1, 25.
Rachinsky et al. (1990) Neuron 5(3), 317-327.
Ratajczak et al., In vivo treatment of human leukemia in ascidmouse model with c-myb antisense oligodeoxynucleotides.Proc. Natl. Acad. Sci. USA. 89:11823-11827 (1992).
Rossi et al., Localization of “Non-extractable” Acetycholinesterase to the Vertebrate Neuromuscular Junction.J. Bio. Chem. 268(25):19152-19159 (1993).
Sarver et al. (1990) Science 247, p. 1222.
Sharma H.S. et al. (1992) Prog. Brain Res. 91, 189-196.
Shoji et al. (1998) J. Drug Target 5, 261-73.
Soni et al. (1998) Hepatology, 28, 1402-10.
Soreq, H., and Seidman, S. (2001) Reviews Neuroscience 2, 294-302.
Sugawa et al. (1998) J. Neurooncol. 39, 237-44.
Soukchareun et al. (1998) Bioconjug. Chem. 9, 466-75.
Shapira et al., A transcription-activating polymorphism in theACHEpromoter associated with acute sensitivity to ant-acetylcholinesterases.Human Molecular Genetics. 9(9):1273-1281 (2000).
Soreq et al., Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G+C-rich attenuating structure.Proc. Natl. Acad. Sci. USA. 87:9688-9692 (1990).
Sternfeld et al., Acetylcholinesterase Enhances Neurite Growth and Synapse Development through Alternative Contributions of Its Hydrolytic Capacity, Core Protein, and Variable C Termini.J. Neurosci. 18(4):1240-1249 (1998).
Sternfeld et al., Excess “read-through” acetylcholinesterase attenuates but the “synthetic” variant intensifies neurodeterioration correlates.Proc. Natl. Acad. Sci. USA. 97(15)8647-8652 (2000).
Shohami et al., Antisense prevention of neuronal damages following head injury in mice.J. Mol. Med. 78:228-236 (2000).
Tavitan et al. (1998) Nat Med 4(4): 467-71.
Triggs et al. (1992) Muscle Nerve 15, 267-72.
Vincent A. (1999) Curr. Opin. Neurol. 12, 545-551.
Wang, J. (1998) Controlled Release 53, 39-48.
Wittbrodt (1997) Arch. Intern. Med., 157, 399-408.
Xu et al. (1999) Endocrinology, 140, 2134-44; and.
Yang et al. (1998) Circ. Res. 83, 552-9.
Seidman et al., (1994) “Over expressed Monomeric Human Acetylcholinesterase Induces Subtle Ultrastructural Modifications in Developing Neromuscular Junctions ofXenopus laevisEmbryos.”J. Neurochem. 62(5):1670-1681.
Seidman et al.,(1995) “Synaptic and Epidermal Accumulations of Human Acetylcholinesterase Are Encoded by Alternative 3′-Terminal Exons.” Mol. And Cell. Biol. 15(6):2993-3002.
Seidman S. et al. (1999) Antisense Nucl. Acid Drug Devel, 9, 333-340.
Waelti et al. (1998) Int. J. Cancer, 77, 728-33.
Soreq et al., (1994) “Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis ex vivo.” PNAS, 91(17):7907-11.
Webster's II New Riverside University Dictionary, p. 1194, 1994.
Evron Tama
Seidman, legal representative Jackilynne
Soreq Hermona
Cooper & Dunham LLP
McGarry Sean R
White John P.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Antisense oligonucleotide against human acetylcholinesterase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotide against human acetylcholinesterase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide against human acetylcholinesterase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4024582